Induction docetaxel platinum 5-FU (TPF) followed by cetuximab-radiotherapy (cetux-RT) versus concurrent chemo-radiotherapy (CT/RT) in patients with N2b/c-N3 non operated stage III-IV squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC 2007-02 phase III randomized trial.

Lionnel Geoffrois, Laurent Martin, P. Garaud, D. De Raucourt, J. Miny, P. Maingon, Cédrik Lafond, C. Tuchais, Christian Sire, E. Babin,

Journal of Clinical Oncology · 2016 · 34 citations · 0 references

Concepts

Abstract

6000 Background: Both CT/RT, and cetux-RT have been established as standard treatments in non-operated locally advanced SCCHN. Taxotere-Platinum-5FU (TPF) is a reference induction regimen in this type of cancer and it is not known whether the addition of induction TPF followed by cetux-RT could improve the outcome of patients with locally advanced SCCHN, as compared to standard CT/RT. Methods: GORTEC 2007-02 trial was restricted to patients (pts) with palpable cervical nodes (N2b/c-N3) and was run in parallel with GORTEC 2007-01 randomized trial testing the addition of concurrent chemotherapy (CT) to cetux-RT in pts with N0-N2a disease. Selection criteria were pts fit for receiving CT with non-metastatic, non-operated stage III-IV SCC of oral cavity, oro/hypopharynx and larynx, regardless of HPV status. Pts were randomized to receive concurrent CT/RT (arm A) or induction TPF plus cetux-RT (arm B). RT was 70 Gy (2 Gy per day, 5 days per week). Concurrent CT was: 3 cycles of carboplatin 70mg/m²/d + 5FU 600mg/m²/d D1-4 (Calais JNCI 1999). Primary end point was progression free survival (PFS). To detect a hazard ratio of 0.66, inclusion of 370 pts was required to achieve 80% power at 2-sided significance level of 0.05. Results: Between 2009 and 2013, 370 pts were randomized. The median follow-up was 31.2 months. There is no difference in PFS, median 11.5 m (arm A) vs 12.5 m (arm B); HR = 0.95, [95%CI 0.72-1.27; p = 0.74]. At the analysis time, 103 deaths were observed in arm A and 107 in arm B. There is no difference in median OS, 24.6 m vs 22.8 m; HR = 1.10; [95%CI 0.84-1.45; p = 0.48]. At 24 months, loco-regional control was 46.6% vs 43.3; HR = 0.97; [95%CI 0.73-1.30; p = 0.85] and distant free metastasis 86.4% vs 92.9% HR = 0.50; [95%CI 0.22-1.11; p = 0.081]. Grade 3-4 neutropenia occurred in 25.8% of pts in arm B vs none in arm A. Conclusions: GORTEC 2007-02 failed to demonstrate any superiority of induction TPF followed by cetux-RT vs CT/RT in this category of very poor prognosis locally advanced SCCHN. CT/RT remains the standard of care in this population. Clinical trial information: NCT01233843.